Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer (GRECCAR6)
|Rectal Cancer||Procedure: Surgery after 11 weeks of delay after chemoradiotherapy. Procedure: Surgery after 7 weeks of delay after chemoradiotherapy||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Randomized Control Trial Comparing the Impact of a Lengthening of the Interval Between the Radiochemotherapy and Surgery (7 Weeks vs. 11 Weeks) on Complete Pathological Response in Rectal Cancer|
- Percentage of pathological complete response after pathological examination of surgical specimen defined by the absence of persistent tumor cell invasion and lymph node (ypT0N0) in group 7 weeks versus 11 weeks in the group [ Time Frame: 6 month ]
- Rates of clinical response to radio-chemotherapy before surgery, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 6 month ]
- Rate of tumor regression, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 6 month ]
- Rates of operative mortality and morbidity at 90 days, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 6 month ]
- Quality of mesorectum resection, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 6 month ]
- Rate of sphincter preservation, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 6 month ]
- Local and distant recurrence rates, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 5 years ]
- Overall survival and disease-free survival rates, comparison between the two groups (7 versus 11 weeks) [ Time Frame: 5 years ]
- Functional results (LARS score) [ Time Frame: 24 months and 36 months ]LARS questionnaire (Low Anterior Resection Syndrome questionnaire) completed at 24 months and 36 months
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||April 2020|
|Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
Experimental: 11 weeks
The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
Procedure: Surgery after 11 weeks of delay after chemoradiotherapy.
Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
Procedure: Surgery after 7 weeks of delay after chemoradiotherapy
Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
D0: Visit of inclusion and randomization After the end of chemoradiotherapy, the patient is seen in consultation by her / him a surgeon who propose him to participate in the study. At the end of the visit if the patient agrees to participate in it, the investigator at each center will conduct the collection of written consent to the inclusion of the patient. Inclusion will be recorded in the e-CRF by the investigator at each center. Randomization (7 or 11 weeks of delay) is performed by the surgeon via the software module Cleanweb randomization.
M1- 1.5 or M2.5 depending of the group randomisation A consultation with the surgeon is held within 15 days (+/- 5 days) of intervention to check the clinical response (tumor regression in rectal tumor distance from the dentate line) and planify surgery. During this visit, the surgeon noted in the e-CRF, clinical findings of the lesion and the results of further investigations.
Not specific exam is requested in the study.
M2 or M3
The anesthesia consultation is planned before the surgery according to the habits of service. Participation in the study does not alter the anesthetic procedures.The patient is admitted the day before surgery in the surgical ward.
During surgery, the operating data are provided on the e-CRF (digital rectal examination under general anesthesia, type of surgery (anterior resection or abdominal-perineal resection), operative time, intraoperative bleeding, macroscopic appearance of the mesorectum, distance from the distal limit of resection). The postoperative complications are noted by the surgeon in the e-CRF during hospitalization (about 10-15 days), and data reporting pathological (Annex 2).
Pathological examination of the specimen of proctectomy is performed according to recommendations for clinical practice using the standard form (Annex 2). The tumor response is evaluated by inclusion of all residual tumor and the response to chemoradiotherapy is graded with the scale of Rodel (Annex 5). A double reading of slides will be made for each patient by two independent pathologists blinded to the randomization group of the patient.
M2 - M5 or M3 - M6 :
Postoperative follow-up :
Following the intervention, no specific consultation is necessary. At follow-up consultations (1 month, 3 months) the surgeon evaluate the postoperative course, planify the stoma closure, noted the potential adverse events and results of morphological examinations (computed tomography, ultrasound, endoscopy) and biological (markers) eventually prescribed.
M6 - M60 :
Cancer surveillance :
Regular follow-up every 3-4 months fo the first two years and every 6 months for the last remaining 3 years (clinical examination, CT-scan and biological marker (CEA))
Please refer to this study by its ClinicalTrials.gov identifier: NCT01648894
|Saint-Antoine Hospital - AP-HP, Department of general and digestive surgery|
|Paris, France, 75012|
|Principal Investigator:||Jérémie Lefèvre, MD||Assistance Publique|